Spojené státy - angličtina - NLM (National Library of Medicine)

actavis pharma, inc. - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan hydrochloride for injection should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

Kanada - angličtina - Health Canada

apotex inc - melphalan (melphalan hydrochloride); buffer solution - solution - 50mg; 10ml - melphalan (melphalan hydrochloride) 50mg; buffer solution 10ml - antineoplastic agents

Kanada - angličtina - Health Canada

juno pharmaceuticals corp. - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - melphalan hydrochloride, quantity: 55.97 mg (equivalent: melphalan, qty 50 mg) - injection, powder for - excipient ingredients: hydrochloric acid; povidone - melphalan injection is indicated for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Kanada - angličtina - Health Canada

auro pharma inc - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg - antineoplastic agents

Kanada - angličtina - Health Canada

eugia pharma inc. - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg

Spojené státy - angličtina - NLM (National Library of Medicine)

apopharma usa, inc. - melphalan (unii: q41or9510p) (melphalan - unii:q41or9510p) - melphalan 2 mg - alkeran tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. alkeran should not be used in patients whose disease has demonstrated a prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg

Kanada - angličtina - Health Canada

marcan pharmaceuticals inc - melphalan (melphalan hydrochloride); buffer solution - solution - 50mg; 10ml - melphalan (melphalan hydrochloride) 50mg; buffer solution 10ml - antineoplastic agents